A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.
about
Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-AnalysisExpanding the antimalarial toolkit: Targeting host-parasite interactionsNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentCrystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesionThe altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transportersInvolvement of HAb18G/CD147 in T cell activation and immunological synapse formation.Importance of N-glycosylation on CD147 for its biological functionsSystematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.Epitope mapping of metuximab on CD147 using phage display and molecular docking.Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion.Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinomaPromoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma.Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgeryExtracellular membrane-proximal domain of HAb18G/CD147 binds to metal ion-dependent adhesion site (MIDAS) motif of integrin β1 to modulate malignant properties of hepatoma cells.Basigin is a druggable target for host-oriented antimalarial interventions.CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma.Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing miceCD147 reinforces [Ca2+]i oscillations and promotes oncogenic progression in hepatocellular carcinoma.An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells.Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinomaInteraction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma.HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells.What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy.Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma.Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.Liver transplantation as a management of hepatocellular carcinoma.One-step Conjugation of Glycyrrhetinic Acid to Cationic Polymers for High-performance Gene Delivery to Cultured Liver Cell.Recurrence of hepatocellular carcinoma after liver transplantation: an update.The roles of CD147 in the progression of gliomas.Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
P2860
Q26771312-D4C51BA1-C607-43DB-AD9F-2BB0BD5E6E22Q26772866-39702FA7-DFC9-4E90-91A9-749F0BAE2E3FQ26851211-4039E266-2054-43FA-929C-27BD077A0FE7Q27650414-5025902F-2172-434C-8222-528EF16D90BFQ28072360-44484FA2-5904-4C43-8247-95884B5D44E5Q33524885-9BDD118A-A5CD-42B0-A18C-CD4217EA7BAFQ33580673-782666A0-9A66-4CDB-844F-1EAD54207726Q34201437-F967CCA7-2C21-48DA-89D6-1ED7F127965DQ34664176-33567231-3C1C-48A7-B693-08639B7ADBC2Q34825106-88B15413-98EC-4C4D-9171-00A512769873Q35096572-8E971B6C-E3C1-4446-ACD8-9ADA78FD8C7BQ35213850-42E67AED-CE41-4C18-857E-AA95B53D2B92Q35216085-C56C902B-65FD-48E3-9F07-FFAD87087D41Q35761108-DE24538E-853F-41BB-B0E7-4E8E0E3EC630Q35762947-2BCDE05A-6B36-4BB0-AA38-093B3DD5029AQ35894355-45E0F64A-F5A6-4494-9A6C-59E928F84055Q36311151-665E74C6-D8FC-4A25-8CCD-44BCC5A3CE1EQ36393363-448D1253-FDC0-459B-9B2D-283BB043C33EQ36544233-D7AFC1DB-07B3-4144-8C4D-FA43B6194DADQ36710986-7F67BA6F-4DF4-4D92-9C65-27FBD59B332FQ36934253-D2D7CA89-88FA-4FD9-8084-62BB5A26DAADQ36962630-9EDE7B43-40C6-4CAC-B8BD-D8313E6114D8Q37212974-43EA4F9A-03A9-4B27-9504-A551DD2EE1E5Q37313173-491B53FE-DD1D-45ED-B2A7-E29BD0469FC7Q37317457-C0B156F6-1991-4E26-861C-912884C04939Q37416242-3DAB29DC-C8B5-4A9C-A407-D4F854B18E08Q37641751-409E392E-0032-4CA9-9FE4-539370262DC1Q37645048-B0B20666-29F2-42D9-823B-544A24EF80D3Q37895616-04E4FE37-E04C-47C5-9E69-FE74475D3703Q37952030-00E9F390-47FD-474B-AB7E-658B2862284FQ37972812-3879F1BB-27C8-4604-A871-28EF8B6D7F1BQ37995306-A7E1718A-8092-4F02-A478-CB71F908BBE4Q38065315-948324A2-3A4E-4348-A5B6-9258D087801EQ38225877-F6CD4749-4F3B-4CD6-B998-DC7DE2FF30E9Q38519906-37BA8ADD-CEB8-4F3A-8794-88BB88850A41Q38593380-B7CAD861-F05C-4662-801C-F4E2E4376C4FQ38594469-8ECE1338-00D9-4101-81B3-D28D600A70C9Q38594492-A673588E-A274-4393-B840-5BDA5DCB50ACQ38635611-1DF65011-DDE7-4B8A-BB35-E5A1631D7B2AQ38795885-20B1698F-1BA6-493E-B43E-0B81DE28CC85
P2860
A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A randomized controlled trial ...... e after liver transplantation.
@en
A randomized controlled trial ...... e after liver transplantation.
@nl
type
label
A randomized controlled trial ...... e after liver transplantation.
@en
A randomized controlled trial ...... e after liver transplantation.
@nl
prefLabel
A randomized controlled trial ...... e after liver transplantation.
@en
A randomized controlled trial ...... e after liver transplantation.
@nl
P2093
P356
P1433
P1476
A randomized controlled trial ...... e after liver transplantation.
@en
P2093
Hui-Jie Bian
Hui-Yun Xu
Jian-Li Jiang
Qiang Feng
Qing Zhang
P2860
P304
P356
10.1002/HEP.21465
P407
P577
2007-02-01T00:00:00Z